⌘K

Login Start Free

Home/Filings/4/0001209191-21-040078

4//SEC Filing

Goater Jeff 4

Accession 0001209191-21-040078

CIK 0001718108other

View on SEC.gov Company Profile

Filed

Jun 10, 8:00 PM ET

Accepted

Jun 11, 8:30 PM ET

Size

18.4 KB

Accession

0001209191-21-040078

Insider Transaction Report

Form 4

Period: 2021-06-10

Surface Oncology, Inc.SURF

DirectorChief Executive Officer

Transactions

Sale
Common Stock
2021-06-11$7.61/sh−15,273$116,226→ 257,000 total
Exercise/Conversion
Common Stock
2021-06-10$4.14/sh+34,727$143,770→ 496,727 total
Exercise/Conversion
Common Stock
2021-06-10$4.14/sh+200,000$828,000→ 462,000 total
Exercise/Conversion
Common Stock
2021-06-11$4.14/sh+10,273$42,530→ 272,273 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-06-10−34,727→ 10,325 total
Exercise: $4.14Exp: 2027-03-02→ Common Stock (34,727 underlying)
Sale
Common Stock
2021-06-10$7.66/sh−234,727$1,798,619→ 262,000 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-06-10−200,000→ 104,104 total
Exercise: $4.14Exp: 2027-03-02→ Common Stock (200,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2021-06-11−10,273→ 93,831 total
Exercise: $4.14Exp: 2027-03-02→ Common Stock (10,273 underlying)

Footnotes (4)

[F1]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $7.56 to $7.82. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
[F2]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $7.58 to $7.64. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
[F3]The stock option is fully vested and exercisable as of the date hereof.
[F4]The stock option vests and becomes exercisable in 48 equal monthly installments after the closing of the Issuer's initial public offering.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Surface Oncology, Inc.

CIK 0001718108

Entity typeother

Related Parties

1

filerCIK 0001656435

Filing Metadata

Form type: 4
Filed: Jun 10, 8:00 PM ET
Accepted: Jun 11, 8:30 PM ET
Size: 18.4 KB

View on SEC.gov